Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features.

Stomper, Paul C.; Herman, Steven D.; Klippenstein, Donald; Winston, Janet S.; Edge, Stephen B.; Arredondo, Mark A.; Mazurchuk, Richard; Blumenson, Leslie E.

doi:10.1148/radiology.197.2.7480682

Cited by 217 publications

(112 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few studies have attempted to directly correlate DCE-MRI findings with prognostic factors such as tumour grade and nodal status in clinical studies of breast cancer [32][33][34][35][36]. None of these studies included pharmacokinetic analysis of DCE-MRI.…”

mentioning

confidence: 99%

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Radjenovic

Dall²,

Ridgway³

et al. 2008

BJR

View full text Add to dashboard Cite

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published versionRADJENOVIC, A., DALL, B. J., RIDGWAY, J. P. and SMITH, M. A. (2008). Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. British Journal of Radiology, 81 (962), 120-128. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 This paper presents a practical clinical application of a quantitative pharmacokinetic model to study histologically confirmed and graded invasive human breast tumours. The hypothesis was that, given a documented difference in capillary permeability between benign and malignant breast tumours, a relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition, it was hypothesised that pharmacokinetic parameters may demonstrate stronger correlation with prognostic factors than the more conventional black-box techniques, so a comparison was undertaken. Copyright and re-use policySignificant correlations were found between pharmacokinetic and black-box parameters in 59 invasive breast carcinomas. However, statistically significant variation with tumour grade was only demonstrated in two permeability related pharmacokinetic parameters: k ep (p<0.05) and K trans

show abstract

mentioning

confidence: 99%

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Radjenovic

Dall²,

Ridgway³

et al. 2008

BJR

View full text Add to dashboard Cite

show abstract

“…Aksillada metastaz olup memede mamografi ve US ile bir lezyon saptanamıyorsa, okult meme kanseri demeden önce tetkik olarak mutlaka MR eklenmeli ve tedavi ona göre yönlendirilmelidir (34,35 MR'ı her ne kadar yüksek derecede sensitif bir yöntem ise de, maliyetinin yüksek olması, hastaların bu yönteme uyumunda sorun olabilmesi ve spesifitesinin düşük olması (%30-95) gibi dezavantajları vardır (32,36). Dolayısıyla hatalı pozitif durumları azaltmak için biyopsi yapılması şarttır (30).…”

Section: Mrunclassified

Occult Breast Cancer

Kebudi¹

2013

J Breasth Health

View full text Add to dashboard Cite

Breast carcinoma is the most common malignancy in women after skin cancer and, after lung cancer, the most frequent cause of cancer death in females. With advances in screening over the past 25 years, fewer than 10% of patients will present with metastatic breast carcinoma at the time of diagnosis. Occult breast carcinoma presenting axillary metastases is uncommon and accounts for less than 1% of newly diagnosed breast carcinoma. However, it continues to be a challenging diagnostic and therapeutic problem. In this review, the current approach to diagnosis and treatment of occult breast cancer is discussed. Okult primer meme kanserleri (OMK), T0N1 (evre II) olarak sınıf-landırılmaktadır. Aksiller metastazı olan OMK insidansı düşük-tür. Mamografi öncesi döneme ait üç geniş seride, bu oran tüm meme kanserleri içinde %0,30-1 (2-4) iken, mamografi dönemin-de dört geniş seride bu oran %0,34-0,88 olarak bulunmuştur (5-8) (Tablo 1).Mamografi, ultrasonografi (US) ve Manyetik Rezonanstaki (MR) gelişmelerle birlikte aksiller metastazlı OMK tanısında azalma söz konusudur. Curie Enstitüsü'nde 1960-1997 yılları arasında 59 hasta tedavi edilmiştir (9). Hastalarda medyan yaş 57 (36-79) idi. Otuz beş hasta (%58) postmenopozal dönemde ve iki hasta hormon replasman tedavisi görmekteydi. On beş hastada (%25) meme kanseri aile öyküsü saptandı. Ayrıca diğer çalışmalarda da, bu hasta grubunda ailesel meme kanseri öyküsü yüksek oranda bulunmuştur (6-8). Yirmi sekiz hastada (%47,5) sol aksiller nodlar ve 31 hastada da (%52,5) sağ aksiller nodlar ön plandaydı. TanıKlinik Muayene: OMK tanılı kadınların yaş ortalaması 45-55 arasıdır (10). Lenf nodlarının ortalama çapını Haagensen ve ekibi (11) ile Andrade ve ekibi (12) 4,7 cm, Curie Enstitüsü ise 3 cm olarak vermiştir (13). Nadiren, karşı memede kanser hikayesi olan hastalarda aksiller metastaz görülebilir (14,15). Bu durumda aksilladaki tutulumun nedeninin karşı taraftaki meme kanserinden mi, yoksa aynı taraftaki memedeki yeni, okult bir kanserden mi olduğunu söylemek zordur.Büyümüş aksiller lenf nodları genellikle selimdir, %70 oranında nonspesifik inflamatuvar veya hiperplastik değişikliklere bağlı, %7 oranında da granülomlara bağlı olarak gelişmektedir (16,17). Geriye kalan olgularda malign bir neden vardır. Kadınlarda en sık primer kanser, memenin adenokarsinomudur. Lenfoma ve metastatik kanserler de diğer sebeplerdir. Cilt melanomu, tiroid, akciğer, over, gastrointestinal ve böbrek hücreli kanserler, prostat kanseri meme bölgesine metastaz yapan kanserler olarak sayılabilir (18)(19)(20).Aksiller adenopatisi olan bir kadında tanı amacıyla yapılacak ilk iş, dikkatli bir anamnez alma ve iyi bir fizik muayenedir. Örneğin diğer lenf nodu bulunan bölgelerde yaygın lenfadenopati viral etyoloji

show abstract

“…Unfortunately, these techniques provide rather limited sensitivity and specificity. Over the past few year contrast material-enhanced breast magnetic resonance [7][8][9][10] (MR) imaging has evolved and has become an important tool in the evaluation of breast abnormalities, with a reported sensitivity as high as 94% -100% and *Corresponding author: Dr Surender Kumar, Associate Professor, Department of Surgery, King George`s Medical University, Lucknow, UP, India, Tel: +919005012189; E-mail: dr_kukku@yahoo.co.in specificity in the range of 37%-97% but unfortunately benign tumors, such as fibro adenomas also enhance to various levels from minimal to intense [11,12], therefore a reliable discrimination cannot be made on the basis of enhancement alone. Similarly 20% of Fine needle aspiration cytology (FNAC) may yield inadequate aspirate and may demonstrate a false negative rate of 6.4% [13] in palpable lumps.…”

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Evaluation of Serum of Breast Cancer Patients using High Resolution Magic Angle Proton Magnetic Resonance Spectroscopy (HR-MAS): A Search for Possible Biomarker?

Kumar¹,

Ahmed²,

AA³

2016

Surgery

View full text Add to dashboard Cite

Journal of Surgery IntroductionCancer of the breast in women is a major health burden worldwide. In the developed countries of the West, breast cancer is the single largest cause of death in women between the ages of 35 and 54, with a mortality rate of 28.4 per 100000 females per year in UK [1] and 20.7 per 100,000 (age-standardized mortality rates) women in US [2]. It accounts for 25% of all malignant disease in woman and approximately one in twelve women in America and UK will suffer from some kind of breast diseases during their lifetime [3]. In India, cancer of the breast has been replacing cancer of cervix as the leading site of cancer in most urban population based cancer registries [4]. Since the early detection of breast cancer improves the prognosis in most cases, regular screening of an increasingly large proportion of the female population has been widely advocated [5,6].Mammography and ultrasound imaging are established as the main non-invasive diagnostic procedure used in the identification of breast cancer in screening population and for further evaluation in already identified cases. Unfortunately, these techniques provide rather limited sensitivity and specificity. Over the past few year contrast material-enhanced breast magnetic resonance [7][8][9][10] (MR) imaging has evolved and has become an important tool in the evaluation of breast abnormalities, with a reported sensitivity as high as 94% -100% and AbstractBackground: Early diagnosis is an important factor for successful outcome in breast cancer. Current existing prognostic and predictive tool like ER, PR and HER2 status have main utility to guide whether a patient should or should not receive adjuvant endocrine or targeted therapy and situation has become more complex after the discovery of genomic tests like oncotype Dx etc. So the need to enhance the understanding of the disease process and treatment response, a hunt for suitable tumor marker is still on.Sample collection: 5-7 ml fasting peripheral venous blood was withdrawn from newly diagnosed breast cancer patients. The subjects were properly matched in terms of age, sex, dietary habits and other parameters. The blood was centrifuged and resultant supernatant serum was put into the 3 ml ependorf tube and the specimen was immediately snap frozen in liquid nitrogen and was transferred to the HRMAS lab where it was stored at -80ºC. HRMAS experiment:The collected samples (Malignant 32, Benign 32 and Healthy Control 28) were thawed and subjected to 800 MHz HRMAS spectrometer. The serum samples were recorded in native form using TSP as an internal standard and a coaxial insert. The spectra were acquired using 1D single pulse and Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with water suppress [PRESET-90 degree-(δ-180°-δ)n-Aq] with a echo time of 40 ms. The HRMAS findings were correlated with the standard histopathological report. Results:The 3D scattered PCA score plot of serum (explaining 83% of the total variance showed distinct group separation among the healthy, fibroadenoma and mal...

show abstract

Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features.

Abstract: MR imaging enhancement of 2.0 or more times had high sensitivity (100%) for invasive carcinomas 8 mm or more in diameter, with moderate specificity (65%). Time-intensity curves showed no significant difference between enhancement of benign and malignant lesions.

Cited by 217 publications

References 0 publications

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Occult Breast Cancer

Evaluation of Serum of Breast Cancer Patients using High Resolution Magic Angle Proton Magnetic Resonance Spectroscopy (HR-MAS): A Search for Possible Biomarker?

Contact Info

Product

Resources

About